Kamada stock
KMDANASDAQKamada Ltd., HealthcareISIN IL0010941198
66Score 66 out of 100, Neutral
Price and trend
79 / 100
Price history
+12% in one yearThe chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 1.7% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 56).
The price is 13% below its 52-week high. Largest decline in 13 years: 82% (March 2014 to November 2014).
Chart figures for advanced users
- SMA 50$8.05
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)56
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.68
- The lowest closing price of the last twelve months.
- Resistance$9.31
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Kamada Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (Israel) and, with a market value of $468.95M, is number 73 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $180.46M (up 12.1% year on year) and earnings of $20.2M (up 39.7%).
- For fiscal 2026, analysts expect on average revenue of $202.96M (up 12.5%) and adjusted earnings per share of $0.48 (up 36.4%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 202 of 714 in Healthcare, median 53.
- The P/E is 18.9 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 18.6).
- Our model puts fair value at $10.72, with the price 24% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $75.27M, financial debt $11.71M.Stability 88
- High dividend yieldDividend yield 5.17%, Drug Manufacturers (Specialty & Generic) median 1.74%.
- Below fair valuePrice 24% below the fair value of $10.72.Valuation 80
Weaknesses
- DilutionShare count up 31% since 2020.Capital allocation 39
Its standout strengths are stability and valuation, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Significantly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.25 and expensive above $15.32 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $13.13 (cash-flow model) and $8.31 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $9.57, at 7.9% it would be $12.44.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12.1% on the twelve months before. Revenue has grown strongly since 2007, at around 16% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 42%, operating 15%, net 11%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 10 Mar 2027in 118 days
- Last reported
- 9 Nov 2026EPS reported $0.14 (expected $0.13)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.480.0%
- Revenue
- $202.96M0.0%
- Earnings per share
- $0.580.0%
- Revenue
- $228.16M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +2.4%2026 guidance reiterated: revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million.
“Based on our first half performance, we are reiterating our 2026 annual guidance of $200 million to $205 million in revenues and $50 million to $53 million of adjusted EBITDA, respectively, representing 12% and 23% growth when comparing 2026 guidance midpoints to 2025 results.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 12 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $1.65M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Tsur DavidSale
14 Sept 2026, Board
- Shares
- 22,827
- Price
- $8.18
- Value
- $186,725
- Tsur DavidSale
9 Sept 2026, Board
- Shares
- 175
- Price
- $8.26
- Value
- $1,446
- Tsur DavidSale
8 Sept 2026, Board
- Shares
- 162,760
- Price
- $8.26
- Value
- $1.34M
Show 1 more
- Tsur DavidSale
7 Sept 2026, Board
- Shares
- 14,238
- Price
- $8.28
- Value
- $117,891
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Kamada
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Collegium PharmaceuticalCOLL $770.98M52
- EvotecEVT.DE $624.43M32
- Alpha TeknovaTKNO $541M43
- EvolusEOLS $491.12M45
- Aquestive TherapeuticsAQST $449.96M29
- BoironBOI.PA $371.89M56
- PharmaSGP HoldingPSG.DE $371.49M80
- Aurora CannabisACB $332.01M44
ETFs that hold Kamada
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.03% | 0.35% | €1.21B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Oct 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.